Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Insulin aspart (Fiasp®) | Prescribe by brand name. For specialist use in pregnancy. |
|
|
Insulin degludec 100 units/ml (Tresiba®) | Amber for type 1 diabetes- specialist initiation. RICaD. Red for Type 2 diabetes. |
|
|
Insulin glargene 300 units/ml (Toujeo®) | Specialist initiation. For patients who require more than 80 units of insulin glargine per day and who are troubled by nocturnal hypos. Transfer to Primary Care should not happen until specialists can demonstrate reduction in nocturnal hypos (e.g. after 3–4 months). RICaD. |
|
|
Keromask® | ||
|
Ketorolac eye drops | ||
|
Lacosamide syrup | ESCA |
|
|
Lacosamide tablets | ESCA |
|
|
Lamotrigine dispersible tablets | ||
|
Lamotrigine tablets | ||
|
Lanthanum tablets | Specialist recommendation. |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
